For a profitable company like UCB, the P/E ratio is a useful shorthand for how much you are paying for each euro of current earnings. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, while slower growth or higher uncertainty tends to justify a lower, more conservative multiple.

UCB currently trades on a P/E of 30.09x. That sits above the broader Pharmaceuticals industry average of 22.23x, but below the peer group average of 64.90x, so the stock is neither extremely cheap nor at the very high end of its peer range on this measure.

Simply Wall St's Fair Ratio for UCB is 32.01x. This is a proprietary estimate of what a "normal" P/E could look like for the company, taking into account factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it blends these elements, the Fair Ratio can give a more tailored anchor than a simple comparison with sector or peer averages.

With the current P/E of 30.09x sitting below the Fair Ratio of 32.01x, this framework suggests UCB may be trading at a discount to what these fundamentals might justify.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 95 top founder-led companies .

Upgrade Your Decision Making: Choose your UCB Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St's Community page give you a simple way to tie your view of UCB's story to numbers by setting your own assumptions for future revenue, earnings and margins. You can then link that forecast to a Fair Value and compare it with the current price. This means two investors can look at the same company and reach very different but clearly framed conclusions. For example, one Narrative may line up with a higher Fair Value around €310 based on stronger epilepsy and rare disease execution, while another may be closer to €209 and reflect concerns around pricing pressure and patent expiries. Each Narrative updates automatically as new news or earnings arrive, so you can always see how fresh information affects your valuation and your potential decision about whether the stock looks attractively priced or expensive against your chosen Fair Value.

For UCB, however, we will make it really easy for you with previews of two leading UCB Narratives:

Each one links the same share price to very different assumptions about earnings, margins and what a reasonable multiple might look like. Your job is to decide which set of assumptions feels closer to how you see the business and its risks.

🐂 UCB Bull Case

Fair value in this bull narrative: €284.65

Gap to that fair value versus the last close of €246.30: about 13.5% undervalued using this framework.

Analyst revenue growth assumption used in the narrative: 11.31% a year.

• Focuses on epilepsy, neuroscience and specialty biologics as long term growth drivers, supported by an expanding pipeline in neurology and immunology.

• Builds in assumptions for improving profit margins, helped by manufacturing investment, digital R&D and broader global access in regions such as the US, Europe and Japan.

• Flags pricing pressure, patent expiries, healthcare cost controls and pipeline risks as key watchpoints that could challenge the thesis if conditions turn out differently.

🐻 UCB Bear Case

Fair value in this bear narrative: €209.22

Gap to that fair value versus the last close of €246.30: about 17.7% overvalued using this framework.

Revenue growth assumption used in the narrative: 8.87% a year.

• Points to pricing pressure, loss of exclusivity on drugs such as Cimzia and Vimpat, and tighter regulation as potential headwinds for revenue and margins over time.

• Highlights concentration in neurology and immunology, plus slower digital adoption, as adding extra sensitivity to clinical setbacks, competition and changing treatment trends.

• Accepts that the pipeline and epilepsy franchise could still support growth, but questions whether the current share price already factors in much of that optimism.

If you want to see these stories in full and test which one lines up better with your own assumptions on growth, margins and valuation, See what the community is saying about UCB .

Do you think there's more to the story for UCB? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include UCB.BR .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com